Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
19 06 2023
Historique:
received: 02 02 2023
accepted: 26 05 2023
medline: 21 6 2023
pubmed: 20 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are related RNA viruses responsible for severe respiratory infections and resulting disease in infants, elderly, and immunocompromised adults

Identifiants

pubmed: 37337079
doi: 10.1038/s42003-023-04990-0
pii: 10.1038/s42003-023-04990-0
pmc: PMC10279679
doi:

Substances chimiques

RNA-Dependent RNA Polymerase EC 2.7.7.48
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

649

Informations de copyright

© 2023. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.

Références

Annu Rev Virol. 2023 May 3;:
pubmed: 37137281
Cell Rep. 2020 Jan 7;30(1):53-60.e5
pubmed: 31914397
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Lancet. 2022 May 28;399(10340):2047-2064
pubmed: 35598608
Virus Res. 2011 Dec;162(1-2):80-99
pubmed: 21963675
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4931-4941
pubmed: 32075920
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):81-5
pubmed: 8552680
Protein Sci. 2018 Jan;27(1):112-128
pubmed: 28836357
Nat Med. 2001 Jun;7(6):719-24
pubmed: 11385510
Viruses. 2021 May 05;13(5):
pubmed: 34063087
Antiviral Res. 2005 Feb;65(2):125-31
pubmed: 15708639
Nature. 2020 Jan;577(7789):275-279
pubmed: 31698413
Nat Commun. 2020 Jan 17;11(1):368
pubmed: 31953395
J Virol. 2002 Feb;76(4):1663-72
pubmed: 11799161
Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2099-2107
pubmed: 31953264
J Virol. 2005 Oct;79(20):13105-15
pubmed: 16189012
Pathogens. 2020 Feb 13;9(2):
pubmed: 32069879
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
Antimicrob Agents Chemother. 2014 Jul;58(7):3867-73
pubmed: 24777090
J Virol. 2005 Feb;79(4):2449-60
pubmed: 15681446
Virology. 2004 Apr 10;321(2):247-59
pubmed: 15051385
Nucleic Acids Res. 2019 Jan 10;47(1):299-309
pubmed: 30395342
PLoS Pathog. 2019 Feb 28;15(2):e1007548
pubmed: 30817806
J Virol. 1999 Jul;73(7):5852-64
pubmed: 10364337
Cell. 2019 Sep 19;179(1):193-204.e14
pubmed: 31495574
Nature. 2022 Oct;610(7931):394-401
pubmed: 36171293
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Virol. 2015 Aug;89(15):7786-98
pubmed: 25995255
PLoS Pathog. 2022 Jun 22;18(6):e1010451
pubmed: 35731802
J Virol. 2013 Mar;87(6):3196-207
pubmed: 23283954
Nat Commun. 2023 Mar 10;14(1):1324
pubmed: 36898997
Nat Commun. 2015 Nov 09;6:8749
pubmed: 26549102
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28652242
F1000Res. 2018 Feb 1;7:135
pubmed: 29744035
Arch Virol. 2019 Jul;164(7):1967-1980
pubmed: 31089958
Virology. 2002 Mar 30;295(1):119-32
pubmed: 12033771
Nat Rev Microbiol. 2021 May;19(5):303-318
pubmed: 33495561
J Biol Chem. 2018 Oct 26;293(43):16761-16777
pubmed: 30206124
J Virol. 2020 Oct 27;94(22):
pubmed: 32847861
Curr Opin Struct Biol. 2016 Feb;36:75-84
pubmed: 26826467
Sci Adv. 2022 Jun 24;8(25):eabo2236
pubmed: 35749502
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583
pubmed: 30880339
Cell. 2015 Jul 16;162(2):314-327
pubmed: 26144317
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
Biochem Mol Biol Educ. 2016 Sep 10;44(5):433-7
pubmed: 27241834
PLoS Pathog. 2017 Dec 27;13(12):e1006803
pubmed: 29281742
Front Microbiol. 2019 Jul 10;10:1490
pubmed: 31354644
J Med Chem. 2019 Apr 11;62(7):3206-3227
pubmed: 30411898

Auteurs

Victoria A Kleiner (VA)

Department of Virology, Immunology & Microbiology, National Emerging Infectious Diseases Laboratories, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.

Thierry O Fischmann (T)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

John A Howe (JA)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Douglas C Beshore (DC)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Michael J Eddins (MJ)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Yan Hou (Y)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Todd Mayhood (T)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Daniel Klein (D)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Debbie D Nahas (DD)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Bob J Lucas (BJ)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

He Xi (H)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Edward Murray (E)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Daphne Y Ma (DY)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Krista Getty (K)

MRL, Merck & Co., Inc., Rahway, NJ, USA.

Rachel Fearns (R)

Department of Virology, Immunology & Microbiology, National Emerging Infectious Diseases Laboratories, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. rfearns@bu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH